VGX-1027

VGX-1027 is an orally active isoxazole compound that exhibits various immunomodulatory properties. VGX-1027 targets macrophages, reducing the production of the proinflammatory mediators TNF-α, IL-1β, IL-10. VGX-1027 has antidiabetogenic effects by limiting cytokine-mediated immunoinflammatory events[1][2][3].

Product Specifications

CAS Number

[6501-72-0]

Product Name Alternative

GIT 27

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Interleukin Related; TNF Receptor

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/VGX-1027.html

Purity

99.67

Solubility

DMSO : ≥ 56 mg/mL

Smiles

O=C(O)CC1CC(C2=CC=CC=C2)=NO1

Molecular Formula

C11H11NO3

Molecular Weight

205.21

Precautions

H302, H315, H319, H335

References & Citations

[1]Stosic-Grujicic S, et al. A potent immunomodulatory compound, (S, R) -3-Phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice. J Pharmacol Exp Ther. 2007 Mar;320 (3) :1038-49.|[2]Danijela Maksimovic-Ivanic, et al. Anticancer properties of the novel nitric oxide-donating compound (S, R) -3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo. Mol Cancer Ther. 2008 Mar;7 (3) :510-20.|[3]K Mangano, et al. Effects of the immunomodulator, VGX-1027, in endotoxin-induced uveitis in Lewis rats. Br J Pharmacol. 2008 Nov;155 (5) :722-30.